Among the RARA activators tested, ATRA had the most pronounced effect, potentially due to its known antioxidant properties that inhibit lipid peroxidation in addition to its ability to activate RARA. These findings suggested that resistance to ATRA in treating lung cancer may be related to the regulation of ferroptosis by RARA and that inhibition of RARA could be a potential target for combination therapy. This evidence concerns the gene RARA and lung cancer.